diabetestalk.net

Medtronic Logo White

New Review Of Selecting The Appropriate Continuous Glucose Monit - Wrcbtv.com | Chattanooga News, Weather & Sports

New Review Of Selecting The Appropriate Continuous Glucose Monit - Wrcbtv.com | Chattanooga News, Weather & Sports

New Review of Selecting the Appropriate Continuous Glucose Monit - WRCBtv.com | Chattanooga News, Weather & Sports New Review of Selecting the Appropriate Continuous Glucose Monitoring System a Practical Approach - touchENDOCRINOLOGY Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected] Peter Adolfsson, Christopher G Parkin, Andreas Thomas, Lars G Krinelke,European Endocrinology , 2018;14(1):Epub ahead of print (Logo: ) To be published in European Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Peter Adolfsson et al, discuss two types of continuous glucose monitoring (CGM) systems are currently available for daily diabetes self-management: real-time CGM and intermittently scanned CGM. Both approaches provide continuous measurement of glucose concentrations in the interstitial fluid; however, each has its own unique features that can impact their usefulness and acceptability within specific patient groups. This article explores the strengths and limitations of each approach and provides guidance to healthcare professionals in selecting the CGM type that is most appropriate to the individual needs of their patients. The full peer-reviewed, open-access article is available here: Disclosure:Peter Adolfsson has received a research grant from Novo Nordisk and consulting fees associated with lectures/meetings from Eli Lilly, Novo Nordisk, Abbott, Dexcom, Medtronic, Nordic Infucare, Roche and Rubin Medical. Christopher G Parkin has received consulting fees from CeQur, Dexcom, Insulet, Johnson & Johnson, Mannkind, Roche Diabetes Ca Continue reading >>

Medtronic's New Business Model: You Only Pay If It Works

Medtronic's New Business Model: You Only Pay If It Works

Medtronic's new business model: You only pay if it works Written by Julie Spitzer| February 21, 2018| Print | Email Medtronic CEO Omar Ishrak, PhD, is taking the medical device company in a slightly different direction: accepting more risk in how it gets paid for its products, according to The Wall Street Journal. Medtronic, which specializes in products such as implantable cardiac devices and insulin pumps, has been signing more and more supply contracts in which prices change based on how well its products work in patients.These outcomes-based contracts are in-line with the shift toward value-based healthcare reimbursement models, Mr. Ishrak told WSJ. Since early last year, Medtronic has signed almost 1,000 contracts that require it to reimburse hospitals if its product Tyrx, an antibacterial sleeve, doesn't protect against infections in patients receiving cardiac-device implants. It also has a deal with the insurance giant Aetna to alleviate some of the reimbursements the insurer pays for Medtronic's insulin pumps if patients' diabetes improve when they switch to a different brand. "Medtronic is focused on technologies to improve outcomes. We use biomedical engineering to alleviate pain, restore health and extend life. Historically we've done that by creating credible evidence that our technologies do change outcomes. But at the end of the day, we and the industry get paid on the technology itself and a promise that those outcomes will actually be changed," Mr. Iskrak told WSJ. He added: "We are moving, just like the rest of healthcare, to a value-based model, where we get paid in some fashion for actually achieving the outcome. It's a step we have to take to make sure that the value we create with our technologies is truly realized. And when it gets realized, we wi Continue reading >>

Medtronic: Big Data Processing Digital Design, Development And Inbound Marketing: Debreeze Interactive

Medtronic: Big Data Processing Digital Design, Development And Inbound Marketing: Debreeze Interactive

Founded in 1949, Medtronic is the worlds largest stand-alone medical technology development company. With offices in 155 countries and 92,000 employees, the company is fortune 500 with clients that include hospitals and healthcare centers around the globe. With thousands of sales team distributed all over the world, the treasure trove of proprietary and sensitive clinical data calls for special attention to security. However, data security and simple user experience usually do not mix. Thats when Medtronic reached out to deBreezeto help streamline the process. The first problem that needed to be addressed was processing a complex and constantly changing clinical data. The output had to be presented in the form of easily digestible and beautiful graphs. The visualizations need to be highly interactive to allow the user to jump across multiple data sets and display the outcome. And most of all, the numbers should be current and the product should be secure. The solution devised was a backend technology that pulls clinical data directly from Medtronic servers in XML and Jason formats, processes the data, and then visualizes it in real-time. To display the output, our user experience design and engineering teams created an intuitive iPad application. Leveraging the highest form of security, the sales team access the application and create timely and compelling presentations displaying real-time data visualizations with just a couple of clicks. Thus, a streamlined global sales team and confidently communicating value proposition. After login, a salesperson will be able to add basic presentation info such as data, name, client name and so on. Alternatively, leveraging machine learning, this can be auto-filled to an actual date, use a location-based info to suggest hospital n Continue reading >>

Twin Cities Business - Medtronic Settles Retaliatory Termination Suit

Twin Cities Business - Medtronic Settles Retaliatory Termination Suit

Health + Health Care | Law + Crime | Other Medtronic Settles Retaliatory Termination Suit A former employee at the med-tech company was allegedly let go after reporting violations of company policies and state and federal laws. Medtronic settled a lawsuit with one of its former sales representatives on Monday. Susan White accused the med-tech company of terminating her after she reported violations of both Medtronics policies and of state and federal anti-fraud laws. Terms of the settlement were not disclosed. Medtronic, which holds its U.S. headquarters in Fridley, hired White for her second stint at the company in December 2011. During her training, White claimed to have witnessed Medtronic employees programming neurostimulation devices, touching and bandaging patients, and promoting off-label uses for devices. If proven true, each of these actions would fall under violation of Medtronics policies, the False Claims Act and the Texas Medicaid Fraud Prevention Act. White said she told multiple company officials, from her direct supervisor to Human Resources, and ultimately to Medtronics Legal Department about the activities she observed. The original court filing claims Medtronic officials responded harshly, labeling White not a team player before ultimately terminating her. White was let go in April 2012. Her retaliation suit was filed in the U.S. District Court for Eastern Texas in March 2015. In the initial complaint, White said she was pursuing reinstatement to the position and seniority that she would have held [if not for] for retaliation. If the reinstatement wasnt feasible, she said shed compromise for twice the amount of back pay plus interest. Additionally, she wanted compensation for litigation costs and other law-related expenses. Continue reading >>

Medtronic Minimed Insulin Pump Recall | Gray And White Law

Medtronic Minimed Insulin Pump Recall | Gray And White Law

Call 888-450-4456 or fill out this form to request a free, no-obligation consultation with one of our experienced attorneys. Medtronic Has Issued a Global Recall for the MiniMed Insulin Pump Important Warning for Diabetic Patients in Kentucky Medtronic has issued a large global recall of its diabetic insulin pump infusion devices. This recall will potentially affect every Kentucky resident that is currently using a Medtronic MiniMed insulin pump system. The global voluntary recall of Medtronics diabetes infusion sets includes all models of Medtronic MiniMed insulin pumps. The period of time for the recall includes devices manufactured before April 2017. This recall will affect thousands of devices already being used by patients in Kentucky and across the United States. This is a very serious recall as the defect in the device can cause serious adverse effects and even death. Defective Vent Membranes Are Leading to Incorrect Insulin Dosages and Hypoglycemia The problem is a defective vent membrane that can become blocked by fluid build-up when the pump is primed after an infusion set change is made. If the blockage occurs, the pump can give the patient too much insulin which can lead to hypoglycemia (low blood sugar) which can cause serous adverse physical problems and in some cases coma or death. The component at the center of this recall is now discontinued but there are thousands of devices already on the market with this dangerous competent in place. The company is hoping that the new design update will reduce or eliminate the risk of this faulty device delivering too much insulin to patients after they perform an infusion set change. The company contacted the FDA to explain their concerns and share information on the problem and its associated risks. The recall was Continue reading >>

Thoracic Evidence | Ethicon

Thoracic Evidence | Ethicon

1 Ethicon retrospective analysis of economic and clinical outcomes comparing the use of Echelon Powered vs. Medtronic non-powered endoscopic surgical staplers to treat patients undergoing video-assisted thoracoscopic surgery lobectomy. Review of 3,006 cases between 2012 and 2015 from the Premier Perspective Hospital Database. Data assessed included length of stay, total hospital cost, supply cost, room & board cost, incidence of transfusion, and incidence of hemostasis-related complications; all p 0.05. 2 Ethicon retrospective analysis of clinical outcomes between Echelon Powered vs. Medtronic non-powered endoscopic surgical staplers among patients undergoing video-assisted thoracoscopic surgery lobectomy. Review of 1,501 cases between 2012 and 2015 from the Premier Perspective Hospital Database (4.8% vs. 14.2%; p=0.0098). 3 Ethicon retrospective analysis of economic and clinical outcomes between Echelon Powered vs. Medtronic non-powered endoscopic surgical staplers among patients undergoing video-assisted thoracoscopic surgery lobectomy. Review of 3,006 cases between 2012 and 2015 from the Premier Perspective Hospital Database. Length of stay: 4.9 vs 5.7 days; p=0.0374, Total hospital cost: $23,785 vs. $26,180; p=0.0078, Supply cost: $5,021 vs. $5,989; p=0.0161, Room & board cost: $6,792 vs. $7,984; p=0.0385, Transfusion: 4.7% vs. 9.3%; p=0.018, Hemostasis-related complications: 8.2% vs. 13.9%; p=0.0218. 4 Ethicon retrospective analysis of outcomes between Echelon Powered vs. Medtronic non-powered endoscopic surgical staplers among patients undergoing video-assisted thoracoscopic surgery lobectomy. Review of 1,051 cases between 2012 and 2015 from the Premier Perspective Hospital Database. Hemostasis-related complications: 4.8% vs. 14.2%; p=0.010. Transfusion: 3.0% vs. Continue reading >>

Medtronic Defibrillator Lead Recalled

Medtronic Defibrillator Lead Recalled

Oct. 15, 2007 -- The FDA today urged heart patients to consult a doctor if they have a Medtronic Sprint Fidelis defibrillator lead. Defibrillators are implanted heart devices that shock dangerous abnormal heart rhythms back to a normal rhythm. The lead is a wire that connects the defibrillator to the heart. Medtronic has identified five patients whose deaths may have been related to a fractured Sprint Fidelis defibrillator lead. Medtronic has voluntarily suspended distribution of its Sprint Fidelis defibrillator leads. More than 268,000 Medtronic Sprint Fidelis leads have been implanted worldwide, according to Medtronic. "We take all matters of product quality very seriously and believe this action is the right thing to do given currently available information," Medtronic President and CEO Bill Hawkins says in a Medtronic news release. Medtronic's decision is in the "best interest of patient safety," says the FDA's Daniel Schultz, MD, in an FDA news release. Schultz directs the FDA's Center for Devices and Radiological Health. The FDA considers Medtronic's action a recall of the Sprint Fidelis leads. But the FDA isn't recommending removing the recalled leads. "We recognize that some patients and health care professionals might inappropriately interpret the word 'recall' to mean that the devices must be surgically removed and returned to the manufacturer. Although the leads should no longer be implanted in patients, we do not mean to imply that these leads should be surgically removed," states the FDA in the news release. The leads continue to function properly in the "vast proportion of patients," states the FDA. There is no test to predict which leads will fail. The FDA agrees with Medtronic's recommendation that defibrillator settings be adjusted at the patient's nex Continue reading >>

Medtronic : Medical Alley Association

Medtronic : Medical Alley Association

March 14, 2018 | Tags: Abbott , Boston Scientific , Ecolab , Featured , Legislature , Medtronic , Members , Minnesota House , Minnesota Senate , Tony Albright Monday, March 12 was Medical Alley Day at the Minnesota State Capitol, bringing together legislators with the health technology companies that power Minnesotas economy and make it the global epicenter of health innovation and care. Members of the House and Senate were able to meet representatives of MAA member companies from all over the health technology spectrum;Rep. Tony Albright (MN-55B) kicked off the day by sharing some of the communitys impressive feats. Over the rest of the day, legislators had a chance to meet representatives from Abbott, Atricure, Boston Scientific, Ecolab, Inspire Medical Systems, Medtronic, and two of the Minnesota companies acquired by Dutch healthcare giant Philips last year, Respirtech and VitalHealth Software, to get a better sense of what conditions they treat and how they treat them. Sen. David Tomassoni trying out Respirtechs inCourage system Senate Majority Leader Paul Gazelka and Lt. Governor Michelle Fischbach We closed the day in the Senate Chamber thanks to Lt. Gov. Fischbach and Majority Leader Gazelka. We look forward to facillitating more of these interactions in the coming weeks, and are thankful to all the companies and legislators who were able to join us! March 13, 2018 | Tags: 3M , Congressman Emmer , Day at the Capitol , Governor Dayton , Medtronic , OneOme , Pops! , Teamvantage Committees continued their work in both the House and the Senate. With only two more weeks before the first committee deadline, both chambers are spending very little time on their respective floors and nearly all of their time in committees. One highlight was that a proposal to align the Continue reading >>

Medtronic Wins Fda Nod, Ce Mark For Avalus Aortic Valve

Medtronic Wins Fda Nod, Ce Mark For Avalus Aortic Valve

Home Medtronic wins FDA nod, CE Mark for Avalus aortic valve Medtronic wins FDA nod, CE Mark for Avalus aortic valve Medtronic (NYSE: MDT ) said today it won CE Mark approval in the European Union and FDA approval in the US for its Avalus pericardial aortic surgical valve designed to treat aortic valve disease. The Avalus is the Fridley, Minn.-based companys next-gen pericardial surgical aortic valve, and features a supra-annular design to improve hemodynamic performance and limit central regurgitation. The valve also features interior-mounted leaflet and frame design for improved durability and a low-profile design with a streamlined valve holder and single, one-cut release for easier implantations, Medtronic said. Medtronic is committed to advancing its surgical portfolio to offer cardiac surgeons a contemporary option to help meet the individual needs of this patient population. By continuing to collaborate with leading cardiac surgeons around the world, we look forward to bringing heart valve replacement solutions like the Avalus valve to assist in expanding access and improving outcomes for clinical and patient communities, heart valve therapies biz GM Rhonda Robb said in a press release. Regulatory clearances came backed by subsets of data from the pivotal Perigon trial of the valve, which examined the use of surgical aortic valve replacements. Results from the trial indicated low rates of adverse valve-related events, high survival and improve hemodynamic performance at 1-year. Patients in the Perigon trial will be followed up to 5 years, Medtronic said. The proven design elements of the Avalus valve were selected with physicians and patients in mind striving to improve upon the latest generation of stented tissue valves while maintaining t Continue reading >>

Bob White Named Executive Vice President And President Of Medtronic's Minimally Invasive Therapies Group; Chris Lee To Assume Leadership Of Medtronic's Asia Pacific Region

Bob White Named Executive Vice President And President Of Medtronic's Minimally Invasive Therapies Group; Chris Lee To Assume Leadership Of Medtronic's Asia Pacific Region

Bob White Named Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group; Chris Lee to Assume Leadership of Medtronic's Asia Pacific Region Bryan Hanson Leaves Medtronic to Become President and CEO of a Public Company DUBLIN - December 19, 2017 - Medtronic plc (NYSE: MDT ) announced today that Bob White, previously Senior Vice President and President of Medtronic's Asia Pacific (APAC) Region, has been named Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group (MITG). In addition, the company announced that Chris Lee, Senior Vice President and President of Medtronic's Greater China Region, will assume the position of APAC Region President. Lee will remain the Interim President of the Greater China Region until a permanent successor is named in the coming weeks. These leadership changes are effective immediately. The leadership changes are a result of Bryan Hanson's departure to become President and CEO of another public, medical technology company, effective today. Hanson was the former Executive Vice President of MITG. "We are pleased to name Bob White and Chris Lee to these new leadership assignments. Their extensive knowledge and expertise of the Medtronic businesses and regions involved - as well as their demonstrated track records of success - will ensure continuity to our overall business strategies and objectives," said Omar Ishrak, Chairman and CEO of Medtronic. "Bob is uniquely qualified to take on the MITG role given his prior leadership experience in the former Covidien company and his most recent role as President of our APAC region, where he was responsible for advancing MITG and our three other groups in the region. Chris has strong experience across Asia Pacific, having previously led the Continue reading >>

New Review Of Clinical Safety And Tolerability Of Vildagliptin - - Newson6.com - Tulsa, Ok - News, Weather, Video And Sports - Kotv.com |

New Review Of Clinical Safety And Tolerability Of Vildagliptin - - Newson6.com - Tulsa, Ok - News, Weather, Video And Sports - Kotv.com |

New Review of Clinical Safety and Tolerability of Vildagliptin - - NewsOn6.com - Tulsa, OK - News, Weather, Video and Sports - KOTV.com | New Review of Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance - touchENDOCRINOLOGY Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected] Chantal Mathieu, Plamen Kozlovski, Pivi M Paldnius, James E Foley, Vikas Modgill, Marc Evans, Carmen Serban; European Endocrinology, 2017;13(2):68-72 (Logo: ) Recently published in European Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Chantal Mathieu et al, discuss vildagliptin - one of the most extensively studied dipeptidyl peptidase-4 (DPP-4) inhibitors in terms of its clinical utility. Over the last decade, a vast panorama of evidence on the benefit-risk profile of vildagliptin has been generated in patients with type 2 diabetes mellitus (T2DM). In this article, we review the cumulative evidence on the safety of vildagliptin from the clinical development programme, as well as reports of rare adverse drug reactions detected during the post-marketing surveillance of the drug. Across clinical studies, the overall safety and tolerability profile of vildagliptin was similar to placebo, and it was supported by real-world data in a broad population of patients with T2DM, making DPP-4 inhibitors, like vildagliptin, a safe option for managing patients with T2DM. The full peer-reviewed, open-access article is available here: Disclosure:Chantal Mathieu serves or has se Continue reading >>

Azbio In The Loop For The Week Of April 23, 2018

Azbio In The Loop For The Week Of April 23, 2018

AZBio In The Loop for the Week of April 23, 2018 The Biotechnology Innovation Organization (BIO) got its start through a need to come together to create one voice for a fledgling industry. So much has happened in 25 years. Watch the video to learn more As BIO celebrates its 25-year anniversary, the upcoming BIO International Convention June 4-7 at the Boston Convention and Exhibition Center will highlight the organizations past and imagine the future Join the AZBio Board of Directors at the Medtronic Tempe Campus on April 26, 2018 from 5:30 7:30 PM for the AZBio Spring Reception. Its a great way to see old friends, make new connections, and get to know members of your community. Learn more and register today INSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated Device INSYS Therapeutics, Inc. (NASDAQ:INSY) announced plans to advance clinical research of dronabinol inhalation using a novel and patented breath-actuated devicelicensed from U.K.-based Senzer Ltd. and accepted by the U.S. Food and Drug Administration (FDA) under an investigational new drug (IND) filingin the second half of 2018. RightBio Metrics announced its RightSpotpH indicator has received an innovative technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the country. VisionGate Reports Important New Research at the 2018 AACR Annual Meeting on howits Cell-CT platform can detect subtle changes in cellular and nuclear morphology of cancer-associated cells (CACs) as a result of the cancer field effect. Looking for Investors? Applications are open for White Hat 2018 All applicantswill know their status by August 1st. MDMA Annual Meeting May 2nd Washington DC Plan to attend MDMAs 2018 Annual Meeting in Continue reading >>

White House Poses New Hurdle For Medtronic-covidien Deal

White House Poses New Hurdle For Medtronic-covidien Deal

WASHINGTON The Obama administration wants to stop corporate deals like a proposed Medtronic acquisition that could enable the company to save millions in U.S. taxes by shifting its headquarters to Ireland. Treasury Secretary Jacob Lew this week urged the finance committees of both chambers of Congress to push legislation that restricts the ability of U.S. corporations to move their headquarters abroad to lower their tax bills. Lew wants the law made retroactive to May, a move that could scuttle Medtronics proposed $42.9 billion acquisition of Dublin-based Covidien. We should prevent companies from effectively renouncing their citizenship to get out of paying taxes, Lew wrote in a letter dated Tuesday to top congressional tax writers. The Medtronic deal and others like it are highly controversial, with some arguing that a flawed U.S. tax system creates an incentive to shift profits offshore through a process known as tax inversion. Medtronic has become a kind of lightning rod, Minneapolis public relations consultant Glenn Karwoski said. Medtronic, however, says saving on taxes is not the primary rationale for the Covidien deal. The companys vice president of corporate taxes, Phil Albert, said in an interview with the Star Tribune that strategic benefits in the combination would enable Medtronic to build a premier medical technology company. Albert said that once Medtronic decided to acquire Covidien, it looked for the best structure for the enlarged company. Ultimately, he said, the right way to do a deal when youre buying a foreign company of this size was the inversion structure. As the Fridley-based company promotes the deal, on Wednesday it launched a Guide to Tax Inversion that aims to clear up what the company calls misperceptions about why it hopes to move its co Continue reading >>

Ambassador Joins Singapore Staff Of Medtronic To Celebrate Their Headquartering In Ireland

Ambassador Joins Singapore Staff Of Medtronic To Celebrate Their Headquartering In Ireland

Ambassador joins Singapore staff of Medtronic to celebrate their headquartering in Ireland Ambassador joins Singapore staff of Medtronic to celebrate their headquartering in Ireland On Monday 2 February, Ambassador Keating joined President of Medtronic Asia-Pacific, Bob White, to welcome the news of the merger of Medtronic and Covidien. Medtronics acquisition of Ireland-based Covidien makes it a world-leading medical technology company, providing life-long solutions for people with chronic disease. In the process, it also becomes Irelands largest company, with a market capitalisation of over US $ 75 billion and global revenues of an estimated US $27 billion and employing approximately 4,000 people across multiple sites. Addressing more than 1,000 Medtronic employees at Singapores Suntec Convention & Exhibition Centre, Ambassador Keating said: Irelands MedTech sector has become one of the leading clusters for medical device products globally. Alongside what is produced locally in Singapore, it is wonderful to see among the cutting-edge devices on display here today, technologies which have been produced in Medtronic and Covidien facilities in Ireland: in Athlone, in Dublin, in Galway and in Tullamore. As drivers of growth in the MedTech sector in Ireland, Ambassador Keating pointed to Irelands strengths in education, talent sourcing, and track record, and invited guests to visit Ireland to experience this first-hand, alongside our beautiful landscapes and our vibrant social life. The event brought together for the first time Singapore-based Medtronic and (formerly) Covidien employees and showcased the product lines of both companies with product demonstrations around the Convention Centre. A town hall session with all employees was to follow, including a televised addre Continue reading >>

More in diabetes